[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350298-105":59,"doc-detail-350298-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","genomics-of-mtap-loss-in-500000-solid-tumor-specimens-profiled-using-comprehensive-genomic-profiling-platforms","Genomics of MTAP Loss in > 500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms","","Methylthioadenosine phosphorylase (MTAP) genomic loss is assessed as an emerging biomarker for PRMT5 and MAT2A inhibitors based on synthetic lethality. MTAP homozygous loss on chromosome 9p21.3 near CDKN2A/B, including specific exon deletions, MTAP expression, and associated coalteration patterns across tumor types, are evaluated. Using hybrid-capture NGS on large tissue and liquid biopsy cohorts and matched RNA/DNA sequencing, the study maps prevalence, concordance, and exon-level effects.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomics-of-mtap-loss-in-500000-solid-tumor-specimens-profiled-using-comprehensive-genomic-profiling-platforms/350298/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomics-of-mtap-loss-in-500000-solid-tumor-specimens-profiled-using-comprehensive-genomic-profiling-platforms/350298.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the clinical relevance of MTAP genomic loss in this study?","Question",{"text":113,"@type":114},"MTAP genomic loss is evaluated as a biomarker for potential sensitivity to PRMT5 and MAT2A inhibitors through synthetic lethality mechanisms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were MTAP loss events measured across tumor samples?",{"text":118,"@type":114},"MTAP complete and partial exon loss, coalteration patterns, and RNA-expression correlations were assessed using hybrid capture–based NGS from tissue biopsies and liquid biopsies, with a subset analyzed by both RNA and DNA sequencing.",{"name":120,"@type":111,"acceptedAnswer":121},"How does liquid biopsy detection relate to tissue biopsy detection for MTAP loss?",{"text":122,"@type":114},"Prevalence estimates from liquid biopsies approximate tissue biopsies when circulating tumor DNA tumor fraction is elevated (ctDNA TF ≥ 20%).",{"name":124,"@type":111,"acceptedAnswer":125},"What did the study find about coalterations associated with MTAP loss?",{"text":126,"@type":114},"MTAP loss shows tumor-type–specific enrichment of other genomic alterations, including CDKN2A/B losses in pan-tumor settings and additional associations such as EGFR in NSCLC, ERBB2 in colorectal cancer, and PTEN in prostate cancer.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},350298,1790184219,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Original Reports | Cancer Genomics  \nGenomics ofMTAP Loss in > 500,000 Solid Tumor Specimens Proﬁled Using Comprehensive Genomic Proﬁling Platforms  \nDean C. Pavlick, BS1  ; Shruthi Rengarajan, PhD1  ; Jessica K. Lee, MS2  ; Deter X. Jin, PhD1  ; Garrett M. Frampton, PhD1  ;  \nBernard J. Fendler, PhD3  ; Andrej Savol, PhD3; Ole Gjoerup, PhD2  ; Hanna Tukachinsky, PhD2  ; Richard S.P. Huang, MD, FCAP2  ; Alexa B. Schrock, PhD2  ; Jeffrey S. Ross, MD, DSc4,5  ; and Andrea Necchi, MD6,7   \nDOI [https://doi.org/10.1200/PO-26-00037](https://doi.org/10.1200/PO-26-00037)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Methylthioadenosine phosphorylase (MTAP) genomic loss is an emerging biomarker for PRMT5 and MAT2A inhibitors based on synthetic lethality. The MTAP gene is located on chromosome 9p21.3 near CDKN2A/B. MTAP homozygous loss across tumor types, speciﬁc exons lost, MTAP expression, and the landscape of coalterations were assessed. |\n| METHODS | 409,755 tissue biopsies (TBx) and 85,801 liquid biopsies (LBx) were sequenced using hybrid capture–based NGS (FoundationOne CDx or FoundationOne Liquid CDx), evaluating all classes of genomic alterations and circulating tumor DNA (ctDNA) tumor fraction (TF) . Additionally, 6,740 TBx were subjected to both RNA and DNA sequencing to compare MTAP gene expression with genomic MTAPloss. |\n| RESULTS | The prevalence of pan-tumor MTAPloss was 11.4% using TBx, with the highest prevalence observed in mesothelioma (32.8%), glioma (32.7%), pancreatic (28.9%), and bladder cancers (26.4%) . Prevalence of MTAPloss on LBx approximated that of TBx when ctDNA TF ≥20%(positive percent agreement [PPA] 5 86.2%) . CDKN2Aloss was not a reliable proxy for MTAPloss ; 33.7% of CDKN2Aloss cases did not have MTAPloss. MTAPloss was enriched with CDKN2A/B losses pan-tumor, EGFR in NSCLC, ERBB2 in colorectal cancer, and PTEN in prostate cancer, while MTAPno_loss was enriched for RB1 pan-tumor, APC in colorectal cancer, CCNE1 in breast and ovarian cancer, and SPOP in prostate cancer. Complete loss (exons 1-8) was observed in 82.9%, multiple exons in 16.5% and exon 8 alone in \u003C1%. MTAPloss, speciﬁcally the number of exons lost, was correlated with reduced RNA expression. |\n| CONCLUSION | MTAPloss is a frequent pan-tumor alteration that predicts potential sensitivity to PRMT5 or MAT2A inhibitors. Although most tumors exhibit complete MTAPloss, 16.5% are characterized by partial MTAPloss where clinical beneﬁt remains uncertain. The genomic coalteration landscape reported here may inform future PRMT5 or MAT2A clinical trials, potentially in combination with other agents. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted April 1, 2026  \nPublished May 14, 2026  \nJCO Precis Oncol 10:e2600037 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nThe methylthioadenosine phosphorylase (MTAP) gene is located on chromosome 9p21.3, approximately 26 kb upstream of the tumor suppressor genes CDKN2A and CDKN2B.1-5 Homozygous loss of this locus, one of the most common somatic alterations in cancer, frequently results in codeletion of MTAP alongside CDKN2A/B.6-9  \nLoss of MTAP function leads to MTA accumulation, which partially inhibits protein arginine methyltransferase 5 (PRMT5) . This creates a metabolic dependency on PRMT5 and methionine adenosyltransferase 2A (MAT2A), rendering  \ntumor cells hypersensitive to their inhibition through synthetic lethality mechanisms. Thus, MTAP homozygous loss has recently emerged as a promising biomarker for PRMT5 and MAT2A inhibitors.10-12 MTA-cooperative PRMT5 inhibitors, such as AMG 193, AZD3470, and TNG462, showed antitumor activity in early-phase trials for MTAP-deleted pancreatic, lung, biliary, and other cancers.9  \nIn a previous pan-cancer analysis of over 50,000 patients, MTAPloss was detected in 9 . 6% of cases, with elevated rates in pancreatic, biliary tract, lung, bladder, and brain cancers, while ","cbCaiq5TiFogdS3U","https://ap.wps.com/l/cbCaiq5TiFogdS3U","pdf",1901523,13,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance\n# Methods","[{\"question\":\"What is the clinical relevance of MTAP genomic loss in this study?\",\"answer\":\"MTAP genomic loss is evaluated as a biomarker for potential sensitivity to PRMT5 and MAT2A inhibitors through synthetic lethality mechanisms.\"},{\"question\":\"How were MTAP loss events measured across tumor samples?\",\"answer\":\"MTAP complete and partial exon loss, coalteration patterns, and RNA-expression correlations were assessed using hybrid capture–based NGS from tissue biopsies and liquid biopsies, with a subset analyzed by both RNA and DNA sequencing.\"},{\"question\":\"How does liquid biopsy detection relate to tissue biopsy detection for MTAP loss?\",\"answer\":\"Prevalence estimates from liquid biopsies approximate tissue biopsies when circulating tumor DNA tumor fraction is elevated (ctDNA TF ≥ 20%).\"},{\"question\":\"What did the study find about coalterations associated with MTAP loss?\",\"answer\":\"MTAP loss shows tumor-type–specific enrichment of other genomic alterations, including CDKN2A/B losses in pan-tumor settings and additional associations such as EGFR in NSCLC, ERBB2 in colorectal cancer, and PTEN in prostate cancer.\"}]","Genomics of MTAP Loss in > 500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms | PDF",1790088300,33,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27d247c0bbe24347fb8a8dd0e7147ba4.webp",983,1315,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48c17aae743553718a9d3db35b60d9a7.webp",982,1314,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dbda1bef03aa43d902f983821a7408c.webp",981,1312,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3943ea8d5be6113c1571f19ff97918a4.webp",980,1311]